



iSonea AsthmaSense® Receives Prestigious US Innovation Award

- *iSonea considered “pioneer in healthcare industry”*
- *Recognised for mobile innovation, strategy*

Melbourne Australia and Severna Park MD USA. — 21 August 2013 — Medical technology company iSonea Limited (ASX: ISN) has been awarded a prestigious US innovation award for its AsthmaSense® Cloud mobile health technology.

The North American Frost and Sullivan 2013 Innovation Leadership Award 2013 acknowledges iSonea’s “outstanding achievement” and superior performance in developing an innovative product featuring leading-edge technologies.

Announcing the award, F&S described iSonea as “a pioneer in the healthcare industry”, commending the product’s ability to easily collect, analyse and communicate asthma data and noting the company’s leadership, innovation, customer service and strategic product development.

Frost and Sullivan industry analyst Vin Lee Nim said: “AsthmaSense app and AsthmaSense Cloud’s data compilation of users’ asthma events clearly illustrates the ‘cause and effect’ by mapping the lifestyle, environmental, and physiological causes of asthma attacks.”

“AsthmaSense app’s programmable reminders and alerts can potentially improve patient adherence to asthma management. This can lead to more diligent monitoring of risks in real-life settings.”

iSonea CEO Michael Thomas said the award was outstanding recognition for the Company’s trend-setting mobile health technologies.

“This award recognises the proprietary technology and innovative design underpinning our products,” he said. “We are extremely proud of our AsthmaSense app and the accompanying Cloud technology, which was a first-in-class advancement in the mobile health asthma market. We are now taking this a step further and will launch our next generation product, the AirSonea™, in Australia within weeks. AirSonea will signal a new age in asthma monitoring via cutting edge mobile health technologies and enhanced patient empowerment for rapid identification and quantification of wheeze.”

The AsthmaSense mobile app tracks asthma symptoms (signs of breathing function, medication usage) and the treatment plan. Used in conjunction with the company’s proprietary Acoustic Respiratory Monitoring (ARM™) system, the app is evolving to integrate wheeze monitoring into the risk-sensing equation, as well as the user’s geographical location, weather, and air quality factors that may affect asthma patients.

Linking the AsthmaSense Cloud with the AsthmaSense app enables the asthma event monitoring data to automatically store patient data and responses in a password-protected cloud vault transfer. AsthmaSense app's programmable reminders and alerts can potentially improve patient adherence to asthma management. This can lead to more diligent monitoring of risks in real-life settings. The AirSonea device will enable real-time, objective wheeze rate monitoring via smartphone for the first time globally.

ENDS

Media Inquiries:

Mr Michael Thomas
Chief Executive Officer
iSonea Limited
+1 410-777-5251
mthomas@iSoneaMed.com

Emma Power
Monsoon Communications
+61 (0) 419 149 525
emmap@monsoon.com.au

Dr Stewart Washer
Chairman
+61 (0) 418 288 212
swasher@isoneaMed.com

Websites: www.iSoneaMed.com, www.SoundAsthma.com

About iSonea Limited

iSonea Limited (ASX:ISN) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smart phones into medical devices--enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.

For more information, please visit www.iSoneaMed.com and www.SoundAsthma.com.

About Frost & Sullivan

For more than 50 years, Frost and Sullivan has developed growth strategies for emerging businesses, the public sector and investment communities. Its Growth Partnership Company collaborates with clients to leverage visionary innovations that address global challenges and related growth opportunities. Its "Growth Partnership" program supports clients by facilitating opportunities that underpin visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to clients through all phases of development, from concept to research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is unique and includes our 360 degree research, comprehensive industry coverage, career best practices and global footprint in more than 40 offices.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.